EXAS

Exact Sciences Corporation

Price

return (12m)

p/e

-95.86

p/bv

8.30

DIVIDEND YIELD

0.00%

EXAS price

Exact Sciences

If you had invested

exposure

years ago

ago, you would now have *

today you would have:

*The amount considers the reinvestment of dividends.

Return on Investment EXAS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

today you would have:

Fundamentals EXAS

Valuation

P/E

-95.86

Sector -3.16

Industry -3.16

P/BV

8.30

Sector 1.80

Industry 1.80

P/Revenue (PSR)

6.14

Sector 2.05

Industry 2.05

EV/EBITDA

-1,336.81

Sector -210.13

Industry -210.13

EV/EBIT

-116.87

Sector -36.38

Industry -36.38

P/EBITDA

-1,251.28

Sector -19.73

Industry -19.73

P/EBIT

-109.39

Sector -67.09

Industry -67.09

P/Total Assets

3.40

Sector 1.06

Industry 1.06

P/Net Current Assets

-10.47

Sector -9.56

Industry -9.56

P/Working Capital

21.79

Sector -93.54

Industry -93.54

EPS

-1.09

Sector -1.78

Industry -1.78

BVPS

12.64

Sector 1.99

Industry 1.99

Efficiency

Gross Margin

69.69%

Sector 41.27%

Industry 41.27%

EBITDA Margin

-2.68%

Sector -21,198.78%

Industry -21,198.78%

EBIT Margin

-6.13%

Sector -35.28%

Industry -35.28%

Net Profit Margins

-6.40%

Sector -35.71%

Industry -35.71%

Asset Turnover

0.15

Sector 0.03

Industry 0.03

Profitability

ROE

-8.66%

Sector -61.33%

Industry -61.33%

ROA

-3.55%

Sector -54.29%

Industry -54.29%

ROIC

-7.31%

Sector -1,801.33%

Industry -1,801.33%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

2.43

Sector 2.91

Industry 2.91

Net Debt / EBITDA

-85.53

Sector -20.88

Industry -20.88

Net Debt / EBIT

-7.48

Sector -3.40

Industry -3.40

Net Debt / Equity

0.57

Sector -34,305.41

Industry -34,305.41

Gross Debt / Equity

0.97

Sector -0.81

Industry -0.81

Equity/Assets

0.41

Sector 0.46

Industry 0.46

Liabilities/Assets

0.59

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

12.94%

Sector -

Industry -

5Y Earnings CAGR

-18.98%

Sector -

Industry -

Fundamentals EXAS

DRAG THE FRAME TO SEE MORE DATA

Assets	Price ($)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
EXAS Exact Sciences Corporation	$0.00	-100.00%	0.00%	-95.86	8.30	-8.66%	-6.40%
PFE Pfizer Inc.	$29.88	31.85%	5.59%	43.90	1.99	4.43%	6.34%
ABBV AbbVie Inc.	$288.24	37.21%	2.31%	53.66	0.00	-%	14.76%
NVO Novo Nordisk A/S	$40.30	-9.03%	4.66%	9.73	5.17	60.28%	35.32%
MRK Merck & Co. Inc.	$146.94	80.36%	2.26%	151.28	8.26	5.07%	3.64%
AZN AstraZeneca PLC	$186.85	13.45%	1.71%	25.01	5.71	24.18%	18.97%
BMY Bristol-Myers Squibb Company	$63.13	44.63%	5.06%	13.78	5.44	44.06%	18.47%
ZTS Zoetis Inc.	$82.11	-32.76%	2.60%	12.71	10.64	64.91%	27.69%
AMGN Amgen Inc.	$460.28	60.27%	2.13%	28.86	21.58	91.47%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$902.90	40.13%	0.41%	21.68	2.96	14.04%	27.86%
HALO Halozyme Therapeutics Inc.	$122.96	80.69%	0.00%	37.10	106.90	173.67%	24.86%
MCK McKesson Corporation	$1,072.00	27.98%	0.34%	25.96	-30.85	-168.45%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$542.50	28.66%	0.00%	32.22	7.01	23.54%	35.00%
CAH Cardinal Health Inc.	$267.82	38.41%	0.81%	34.74	-21.86	-63.98%	0.67%
ARGX argenx SE	$894.77	7.61%	0.00%	13.26	-	-%	25.42%
HRMY Harmony Biosciences Holdings Inc.	$32.47	5.70%	0.00%	12.39	2.25	20.46%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

today you would have:

*This calculation reflects price variation only.

EXAS - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT Exact Sciences

Exact Sciences Corporation

Average Investor10 user rating

4.0 (2 people)

United States

31 years

Founded: 1995

2001

Time since IPO - 25 years

4.110

Employees

Exact Sciences Corporation (United States) is listed on the Nasdaq and has a market capitalization of $19.93 billion, with shareholders equity totaling $2.40 billion.

The company employs approximately 4.110 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Exact Sciences Corporation reported $3.25 billion in revenue, generating net income of $-207.94 million.

Key financial metrics include a P/E ratio of -95.86, a price-to-book (P/B) ratio of 8.30, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker EXAS.

Market cap

$19.93 billion

Net worth

$2.40 billion

$2,401,050,000.00

Assets

$5.86 billion

$5,860,630,000.00

Total Shares Outstanding

190.00 million

190,000,000

Average Daily Trading Volume

$2.86 million

$2,857,152.96

Sector

Health Care

Industry

Biotechnology

EXAS

EXAS revenue and profits

Financial Results EXAS

DRAG THE FRAME TO SEE MORE DATA

EXAS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$1,072.00 25,46% (12M)

P/E

25.96

0.34%

ROE

-168.45%

P/BV

-30.85

CAH - Cardinal Health

$267.82 36,55% (12M)

P/E

34.74

0.81%

ROE

-63.98%

P/BV

-21.86

MRK - Merck & Co.

$146.94 76,32% (12M)

P/E

151.28

2.26%

ROE

5.07%

P/BV

8.26

ABBV - AbbVie

$288.24 35,79% (12M)

P/E

53.66

2.31%

ROE

P/BV

0.00

PFE - Pfizer

$29.88 30,58% (12M)

P/E

43.90

5.59%

ROE

4.43%

P/BV

1.99

AZN - AstraZeneca

$186.85 12,36% (12M)

P/E

25.01

1.71%

ROE

24.18%

P/BV

5.71

BMY - Bristol-Myers Squibb

$63.13 41,40% (12M)

P/E

13.78

5.06%

ROE

44.06%

P/BV

5.44

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$1,072.00 25,46% (12 M)

P/L

25.96

0.34%

ROE

-168.45%

P/VP

-30.85

CAH - Cardinal Health

$267.82 36,55% (12 M)

P/L

34.74

0.81%

ROE

-63.98%

P/VP

-21.86

MRK - Merck & Co.

$146.94 76,32% (12 M)

P/L

151.28

2.26%

ROE

5.07%

P/VP

8.26

ABBV - AbbVie

$288.24 35,79% (12 M)

P/L

53.66

2.31%

ROE

P/VP

0.00

PFE - Pfizer

$29.88 30,58% (12 M)

P/L

43.90

5.59%

ROE

4.43%

P/VP

1.99

AZN - AstraZeneca

$186.85 12,36% (12 M)

P/L

25.01

1.71%

ROE

24.18%

P/VP

5.71

BMY - Bristol-Myers Squibb

$63.13 41,40% (12 M)

P/L

13.78

5.06%

ROE

44.06%

P/VP

5.44

Frequently Asked Questions

What is the price of Exact Sciences (EXAS) today?

The current price of Exact Sciences (EXAS) is $0.00. The stock began the year trading around $101.56 and is currently priced at $0.00. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Exact Sciences (EXAS) pay dividends?

Exact Sciences (EXAS) did not pay dividends over the past year.

Is Exact Sciences (EXAS) a good investment?

Exact Sciences (EXAS) is currently trading at $0.00 with a P/E ratio of -95.86. This represents a -4,644% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Exact Sciences (EXAS) stock?

You can buy Exact Sciences (EXAS) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol EXAS and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Exact Sciences (EXAS) yield today?

Over the past month, Exact Sciences (EXAS) has returned 0.00% — 0.00% over the past year, and 0.00% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Exact Sciences (EXAS) today at the current price of $0.00 your total investment would be $0.00.

Based on historical performance, the investment would have grown to approximately:

$0.00 after 1 year
$0.00 after 5 years
$0.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

EXAS

Exact Sciences Corporation

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment EXAS

Target price created!

Delete target price?

Your Target Price strategy deserves unlimited alerts

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING EXAS WITH OTHER STOCKS

ABOUT Exact Sciences

Exact Sciences Corporation

United States

31 years

2001

4.110

PROFIT X PRICE EXAS

Financial Results EXAS

EXAS cash flow

Asset, Revenue and Profit Growth - EXAS

EXAS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

MRK - Merck & Co.

ABBV - AbbVie

PFE - Pfizer

AZN - AstraZeneca

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

MRK - Merck & Co.

ABBV - AbbVie

PFE - Pfizer

AZN - AstraZeneca

BMY - Bristol-Myers Squibb

Frequently Asked Questions